anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Mowat-Wilson syndrome (MOWS) is a rare congenital disease caused by haploinsufficiency of ZEB2, encoding a transcription factor required for neurodevelopment. MOWS is characterized by intellectual disability, epilepsy, typical facial phenotype and other anomalies, such as short stature, Hirschsprung disease, brain and heart defects. Despite some recognizable features, MOWS rarity and phenotypic variability may complicate its diagnosis, particularly in the neonatal period. In order to define a novel diagnostic biomarker for MOWS, we determined the genome-wide DNA methylation profile of DNA samples from 29 individuals with confirmed clinical and molecular diagnosis. Through multidimensional scaling and hierarchical clustering analysis, we identified and validated a DNA methylation signature involving 296 differentially methylated probes as part of the broader MOWS DNA methylation profile. The prevalence of hypomethylated CpG sites agrees with the main role of ZEB2 as a transcriptional repressor, while differential methylation within the ZEB2 locus supports the previously proposed autoregulation ability. Correlation studies compared the MOWS cohort with 56 previously described DNA methylation profiles of other neurodevelopmental disorders, further validating the specificity of this biomarker. In conclusion, MOWS DNA methylation signature is highly sensitive and reproducible, providing a useful tool to facilitate diagnosis.
OBJECTIVE: This investigation seeks to examine the association between serum vitamin D concentrations and the prevalence of sleep disorders, additionally elucidating the causal relationship via Mendelian Randomization (MR) analysis.
MATERIALS AND METHODS: This research employed data from the National Health and Nutrition Examination Survey (NHANES) 2011-2016, focusing on adults aged 20-50 years reporting sleep disorders. The research encompassed 4913 American adults. Weighted multivariable logistic regression models and cubic spline analyses were utilized to evaluate the association between serum vitamin D concentrations and the incidence of sleep disorders. Additionally, a two-sample Mendelian Randomization analysis was performed to evaluate the potential causal link between serum vitamin D concentrations and the risk of sleep disorders.
RESULTS: Within the 2011-2016 NHANES cohort of the U.S. population, a notable inverse association was detected between serum vitamin D concentrations and sleep disorders (β =  - 3.81, 95% CI: - 6.10 to - 1.52, p = 0.003). After multivariate adjustments, a higher incidence of sleep disorders was associated with lower vitamin D Concentrations (OR 1.52, 95% CI 1.10-2.10, trend p = 0.014). Restricted cubic spline regression analysis indicated a linear association between serum vitamin D concentrations and sleep disorders(non-linearity p > 0.05). Lastly, the two-sample MR analysis yielded evidence supporting a potential causal connection between serum vitamin D concentrations and sleep disorders, with each unit increase in genetically predicted serum vitamin D reducing the odds ratio to 0.78 (95% CI 0.61-0.99, p = 0.044).
CONCLUSIONS: These results imply that lower vitamin D concentrations in the population might correlate with a heightened risk of sleep disorders, suggesting the importance of considering vitamin D supplementation when treating sleep disorders.
Participants are provided access to the pretest one week before the training. On the day of training, when the trainers arrive, participants have a final opportunity to complete the baseline survey before the intervention. Tablets will be available to complete pre- and post- surveys. The training for management takes 3-4 hours, and for staff, one hour. For consistency and feasibility, both trainings are conducted by the same trainers at the same visit. Immediately after the intervention, participants complete the post-intervention seminar evaluation assessing knowledge and attitudes/comfort in serving SGM clients.
Sorghum is a staple crop grown in the poorest and most food-insecure regions of Ethiopia. But storage insect pests are its key constraints that have been causing considerable loss. Accordingly, an assessment of the prevalence of insect pests and the associated loss of sorghum stored under farmers' traditional storages was done in randomly selected major sorghum-growing kebeles of Kena District using a nested design between November 1, 2019 and December 30, 2020. It was conducted through the sampling of one kg of grain from a total of 360 randomly selected farmers' storages. Pests' abundance was determined by dividing the total number of individual species by the total number of samples. A count and weight method was used to estimate percent grain damage and weight loss by pests. Sitophilus zeamais, Sitophilus oryzae, Sitotroga cereallella, Tribolium castaneum, Tribolium confusum, Cryptolestes ferrugineus, Cryptolestes pusillus, Rhyzopertha dominica, and Plodia interpunctella were the pests identified from grain samples. When compared to mid-latitude, where they were found in the range between 2.36± 0.21 and 17.50±0.98 mean number of species, all of these pests had a considerably (p < 0.05) larger distribution in low-land kebeles, where they predominated in the range between 5.44±2.00 and 23.61±1.75 amean number. During the nine-month storage period, the degree of pest infestation, percentage of grain damage, and weight loss were significantly (p < 0.05) higher in the bamboo bins when no management measures were implemented in the mid-land and low-land kebeles, respectively, than in the barn. Consequently, bamboo bin storage was considered ineffective for sufficient sorghum grain protection against pests and the associated loss over a longer storage period. But barn storage and the use of cultural pest management practices performed better in protecting stored sorghum from pests. Therefore, improving the bamboo bin storage method is needed to improve its grain protection efficacy.
Parents in the experimental group were randomly assigned. Parents in the experimental group will be trained with parent fever management training material via home visits. Repeated measurements will be made one month after the training and at 3 months. Parent fever management training material was created by the researcher according to the literature. Opinions of experts in the field were obtained for the suitability of the training booklet.
The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
A method includes receiving sensor data from a device worn on one or more digits of a test subject. The method including determining physiological parameter(s) from at least a first portion of the sensor data acquired during a test session. The method including associating the determined physiological parameter(s) with the testing session. The method including authenticating the device by i) determining identification data using at least a second portion of the sensor data, the identification data including identifiable characteristic(s) of the one or more digits; ii) accessing authentication data that includes one or more authentication characteristics; and iii) comparing the identification data with the authentication data to determine a match to authenticate the device. The method including generating a chain of custody determination based at least in part on the authentication of the device. The method including associating the chain of custody determination with the testing session.
Cell cycle dysregulation leading to uncontrolled growth is a primary characteristic of malignancy. GSG2, a mitosis-related kinase, affects the normal cell cycle by interfering with the normal dissociation of centromere cohesion, and its overexpression has been shown to play an important role in cancer cells. Here, we investigated the function of GSG2 as a tumor promoter in endometrial carcinoma and its relationship with the immunological microenvironment. We used immunohistochemistry to identify a correlation between the development and prognosis of GSG2 and endometrial cancer. Cell and animal experiments confirmed that GSG2 has a protumorigenic phenotype in endometrial cancer cell lines. Furthermore, using GeneChip analysis and a tumor-immune coculture model, we observed a link between GSG2 expression and the composition of the immune microenvironment. Therefore, we concluded that the activation of the PI3K/AKT pathway by GSG2 may impact DNA repair, disrupt the cell cycle, and regulate the immune response, all of which could increase the ability of EC cells to proliferate malignantly. Consequently, it is anticipated that GSG2 will be a viable therapeutic target in endometrial carcinoma.
The healing of a surface wound is promoted by contacting the wound surfaces with a suspension of particles of collagen and a glycosaminoglycan that is chemotactic of fibroblasts and/or endothelial cells. Typical glycosaminoglycans that exhibit the desired chemotaxis are heparin, heparan sulfate, and alginate. Two or more glycosaminoglycans can be present in the suspensions. Collagen and glycosaminoglycan are present as a dry powdered suspension of particles. Preferably, collagen is present in the suspension in the order of 7-10 mg/ml; while the glycosaminoglycan is present in much lower concentrations, e.g., 250-350  mu g/ml. Application of the collagen/glycosaminoglycan suspension to open wounds greatly increases the rate of healing. The invention includes, an article, useful in the therapy for surface wounds, comprising the suspension of particles on a gauze, bandage tape or the like.
Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
The invention provides for the use of antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit anti-mycobacteria activity, including the mycobacterium causing tuberculosis. Multiple compounds were synthesized and screened for anti-tuberculosis activity. Disclosed herein are a series of compounds with anti-tuberculosis activity, including six leads that completely inhibited bacterial growth at 5 micrograms per ml or less. Three of these compounds were tested to determine MIC and these ranged between 1 and 4 micrograms per ml against both drug susceptible Mycobacterium tuberculosis strains and strains that are multi-drug resistant (MDR) including XDR strains. The compounds developed are derived from parent compound nitazoxanide, which had no inhibitory activity in the stringent testing format used herein. The derivatives were synthesized using a di-nitro-thiophene or 4-Chloro-5-Nitro-thiazole scaffold and R groups connected via a peptide bond (NHCO) to cyclic compounds such as benzene, thiophene or furans. Many of these compounds have broad spectrum activity against Gram positive bacteria including Staphylococcus aureus (MRSA) and Staphylococcus epidermidis. Several of these lead compounds were not toxic for mice at 200 mg/Kg doses administered over a period of three days.
One treatment of chemotherapy every 3 weeks. Chemotherapy will either be 2 doses of 20 mg orally (PO) (12 hrs prior and immediately before treatment) or 1 dose via IV. The total dose per cycle is 20-40 mg every 3 weeks for 18 weeks.
BACKGROUND: Breakthrough cancer pain (BTcP) has a negative impact on patients' quality of life, general activities, and is related to worse clinical outcomes. Fentanyl inhalant is a hand-held combination drug-device delivery system providing rapid, multi-dose (25μg/dose) administration of fentanyl via inhalation of a thermally generated aerosol. This multicenter, randomized, placebo-controlled, multiple-crossover, double-blind study evaluated the efficacy, safety, and tolerability of fentanyl inhalant in treating BTcP in opioid-tolerant patients.
METHODS: The trial was conducted in opioid-tolerant cancer patients with 1 ~ 4 BTcP outbursts per day. Each patient was treated and observed for 6 episodes of BTcP (4 with fentanyl inhalant, 2 with placebo). During each episode of targeted BTcP, patients were allowed up to six inhalations, with an interval of at least 4 min between doses. Primary outcome was the time-weighted sum of PID (pain intensity difference) scores at 30 min (SPID30).
RESULTS: A total of 335 BTcP episodes in 59 patients were treated. The mean SPID30 was -97.4 ± 48.43 for fentanyl inhalant-treated episodes, and -64.6 ± 40.25 for placebo-treated episodes (p < 0.001). Significant differences in PID for episodes treated with fentanyl inhalant versus placebo was seen as early as 4 min and maintained for up to 60 min. The percentage of episodes reported PI (pain intensity) scores ≤ 3, a ≥ 33% or ≥ 50% reduction in PI scores at 30 min, PR30 (pain relief scores at 30 min) and SPID60 favored fentanyl inhalant over placebo. Only 4.4% of BTcP episodes required rescue medication in fentanyl inhalant group. Most AEs were of mild or moderate severity and typical of opioid drugs.
CONCLUSION: Treatment with fentanyl inhalant was shown to be a promising therapeutic option for BTcP, with significant pain relief starting very soon after dosing. Confirmation of effectiveness requires a larger phase III trial.
TRIAL REGISTRATION: ClinicalTrials.gov: NCT05531422 registered on 6 September 2022 after major amendment, NCT04713189 registered on 14 January 2021.
Coadministration of ergotamine with potent CYP 3A4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities (See PRECAUTIONS: Drug Interactions), with some cases resulting in amputation. There have been rare reports of cerebral ischemia in patients on protease inhibitor therapy when ergotamine was coadministered, at least one resulting in death. Because of the increased risk for ergotism and other serious vasospastic adverse events, ergotamine use is contraindicated with these drugs and other potent inhibitors of CYP 3A4 (e.g., ketoconazole, itraconazole) (See WARNINGS: CYP 3A4 Inhibitors).

Ergomar® Sublingual Tablets may cause fetal harm when administered to pregnant women. Ergomar® Sublingual Tablets are contraindicated in women who are or may become pregnant. If this drug is used during pregnancy or if the patient becomes pregnant while taking this product, the patient should be apprised of the potential hazard to the fetus. Peripheral vascular disease, coronary heart disease, hypertension, impaired hepatic or renal function and sepsis.

Hypersensitivity to any of the components.
Cosmetic and/or dermatological composition for treating keratinic fibres comprises a carrier, at least one 2-electron oxidoreductase enzyme, at least one substrate for the enzyme, and at least one basic amino acid. Preferably the enzyme is an animal, microbial or recombinant uricase and is present in an amount of 0.01-20 (preferably 0.1-5) wt.%. The substrate is selected from uric acid and its salts and is present in an amount of 0.01-20 (preferably 0.1-5) wt.%. The amino acid is histidine, lysine, arginine, ornithine or citrulline and is present in an amount of 0.01-20 (preferably 0.05-5) wt.% The composition can contain 0.0005-12 wt.% of an oxidation dye precursor selected from p-phenylenediamines, "double bases", o- or p-aminophenols and heterocyclic bases. The composition can contain 0.0001-10 wt.% of a coupler selected from m-phenylenediamines, m-aminophenols, m-diphenols and heterocyclic couplers. The composition can also contain a direct dye. The carrier is water or a mixture of water and an organic solvent. The composition contains 1-40 (preferably 5-30) wt.% organic solvent. The composition has a pH of 5-11, preferably 6.5-10.  Used for bleaching human hair by applying the composition, optionally containing an auxiliary oxidising agent, and then rinsing; for dyeing human hair by applying a composition as above containing an oxidation dye precursor and optionally a coupler; for permanent waving of human hair by applying a reducing composition, putting the hair under tension, optionally rinsing the hair, applying a composition as above, and optionally rinsing the hair.
Prevalence of celiac disease is on a steep rise in Western countries, but due to difficult diagnosis the majority of patients remain unrecognized. Undiagnosed celiac disease causes incremental burden to the health care and predisposes to severe complications. On the other hand, increasing screening in at-risk groups of celiac disease frequently detects seropositive subjects with no obvious symptoms and/or still normal small-bowel mucosal morphology. At present the natural history and benefits of an early diagnosis in such individuals is poorly known. Further, the endoscopic demonstration of the small-intestinal damage required for the diagnosis is unpleasant, expensive and often misleading. New serology-based diagnostic criteria have been suggested but prospective data is lacking. Aims of the present study are to improve the diagnostic yield and accuracy of the current diagnostic methods and to develop novel non-invasive methods and biomarkers for early detection of celiac disease. In addition, the investigators will evaluate natural history of celiac disease in screening-detected asymptomatic children and in those with positive serology but normal histology, and form a large database for future clinical and translational studies. The study and patient collection are to be conducted at the pediatric clinics in Finland and in Romania. All children referred due to suspicion of celiac disease or gluten sensitivity will be asked to participate to the study. Patient samples and clinical information are collected during the routine visits and the study does not include any additional visits or endoscopies. The total duration of the study is 10 years but data will be analyzed on-line.
The middle tier (Got Your Back) will work closely with the CORE case managers to augment their work in housing support, transportation assistance, mental healthcare referrals, childcare assistance, substance use program referrals, food insecurity support and health insurance needs. The retention specialist will additionally provide this middle tier 2 reminders for appointments; check ins once per week; follow ups for missed appointments or off pill counts; support with scheduling appointments for limited availability; meetings with the health educators for information on HIV or ART; and re-motivation for treatment at the 6 and 9 month marks of participation.
The invention discloses an external patch for treating children's hydrocephalus. The external patch is composed of the following main raw materials in parts by weight: 20 to 40 parts of platycladi seed, 4 to 9 parts of osbeckia chinensis, 5 to 10 parts of rhizoma arisaematis, 5 to 9 parts of bunge cherry seed, 6 to 12 parts of saposhnicovia divaricata, 5 to 15 parts of dahurian angelica root, 4 to 8 parts of notopterygium root, 3 to 6 parts of valeriana wallichii, 3 to 5 parts of prepared rehmannia root, 4 to 8 parts of Chinese yam, 6 to 9 parts of white stiff silkworm, 5 to 10 parts of cornus officinalis, 3 to 6 parts of kendir leaf, 3 to 6 parts of tree peony bark, and a proper amount of pig bile. The external patch is developed on the basis of the pathogenic mechanism of the children's hydrocephalus. The raw materials are compounded according to the TCM differentiation theory, and the raw materials can cooperate with each other to generate a synergetic effect. The raw materials are made into a patch, and thus the medicinal components can penetrate into human body and then directly act on the brain. The external patch has the functions of warming yang for resolving fluid retention, activating blood circulation to remove stasis, freeing the orifices, and inducing diuresis, and has a very good curative effect on children's hydrocephalus.
Preparation (A) with wound-healing activity, obtained from the pupae of Diptera, is new. ACTIVITY : Vulnerary. An 83 year old patient with a chronic ulcus cruris that had not responded to standard treatments was treated daily with a extract of dipteran pupae, in aqueous form and as lyophilizate. The wound was covered with gauze and bound with a compression bandage. Within 7 days the wound showed strong granulation, without residual fibrinous deposits, and after 59 days the ulcer was cured completely. MECHANISM OF ACTION : None given.
Global derived data indicate that compared to most ethnicities, people of South Asian (SA) descent shoulder a heavier burden and mortality rate for atherosclerotic cardiovascular disease (ASCVD). They are younger at the time of first hospitalization for heart failure and exhibit more high-risk features upon discharge. Canadian data indicate that SAs presented to the hospital later during acute myocardial infarction and are more likely to have an anterior location of infarction. They also tend to be younger at the time of cardiac catheterization than those of European descent and are more likely to have significant left main, multivessel, and distal coronary artery disease. SAs appear to have comparatively pro-atherosclerotic lipid profiles - more small dense LDL particles, lower HDL-C levels, and hypertriglyceridemia - and demonstrate a higher prevalence of diabetes, metabolic syndrome, central adiposity and inflammation.

People of SA descent are markedly underrepresented in clinical trials, and it remains unclear as to whether many of the life-saving therapies are generalizable to this population. The REDUCE-IT Canada SA Study aims to determine the generalizability of the REDUCE-IT study results to people of South Asian descent with known ASCVD living in Canada. Specifically, the study will ascertain the proportion of South Asian individuals that meet the Health Canada indication for IPE; the alignment of the participants' baseline characteristics with those of the REDUCE-IT cohort; the proportion of study participants who have access to private and/or public coverage.
Potential Harm to the Fetus

The use of KRINTAFEL during pregnancy may cause hemolytic anemia in a G6PD-deficient fetus. Even if a pregnant woman has normal levels of G6PD, the fetus could be G6PD deficient. Advise females of reproductive potential that treatment with KRINTAFEL during pregnancy is not recommended and to avoid pregnancy or use effective contraception for 3 months after the dose of KRINTAFEL [see Use in Specific Populations (8.1, 8.3)].

Potential Harm to the Breastfeeding Infant

A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to KRINTAFEL through breast milk. Infant G6PD status should be checked before breastfeeding begins. KRINTAFEL is contraindicated in breastfeeding women when the infant is found to be G6PD deficient or the G6PD status of the infant is unknown [see Contraindications (4)]. Advise the woman with a G6PD-deficient infant or if the G6PD status of the infant is unknown not to breastfeed for 3 months after the dose of KRINTAFEL [see Use in Specific Populations (8.2)].
A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Control of mammalian gastro-intestinal tissues growth and repair is facilitated by the use of the proteins, making the proteins candidates for therapies.
Experimental performs Strengthening exercises of core.10 reps , 3 sets of each.Prone plank(10 sec hold)(18) ,Side plank (8 sec hold),Bridging (8 sec hold)(19),Bird dog (10 reps ,3 sets),Leg drop (10 reps, 3 sets)(15),Dying bug with their regular swimming practice. First 2 weeks simple strengthening exercises.Next 4 weeks stability ball exercises. Dying bug without stability ball. And strengthening exercises of UL and LL with theraband ,10 reps each.Upper limb: Latissimus dorsi,Serratus anterior, Upper trapezius.Lower Limb: Flexors of hip, Extensors of hip,Plantar flexors.